News
The latest developments in TMS research and treatment, curated by our team.
-
“Could Accelerated TMS for Depression Become Standard?”
Psychology Today
Transcranial magnetic stimulation (TMS) was first approved for the treatment of major depressive disorder (MDD) in 2008. Because it worked well for depression by using a strong magnetic field to stimulate key brain areas, TMS was recommended early on by the American Psychiatric Association in its 2010 Practice Guidelines (APA, 2010).
-
“Cognitive” Subtype of depression may be resistant to common drugs
Technology Networks
Scientists at Stanford Medicine conducted a study describing a new category of depression — labeled the cognitive biotype — which accounts for 27% of depressed patients and is not effectively treated by commonly prescribed antidepressants.
-
UBC Scientist Dr. Fidel Vila-Rodriguez describes TMS
Capture Queue
Dr. Fidel Vila-Rodriguez is a clinical scientist at the University of British Columbia’s NINET Lab studying repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression, Parkinson’s disease, and OCD. In the second episode of the Capture Queue podcast, he explains what rTMS is, how it functions, and the work he’s doing to push for wider access to rTMS and similar treatments.
-
FDA clears NeuroStar TMS for adolescent depression treatment
Investing.com
MALVERN, Pa. – Neuronetics , Inc. (NASDAQ:STIM), a medical technology company, has received U.S. Food and Drug Administration (FDA) clearance for its NeuroStar Advanced Therapy system as an adjunct treatment for major depressive disorder (MDD) in patients aged 15-21.
-
CBS reports magnetic brain stimulation treatment brings a new hope in fight against depression
CBS News
Stanford’s SAINT (which stands for Stanford Accelerated Intelligent Neuromodulation Therapy) program demonstrates excellent results in latest clinical trial – almost 80% of participants saw their severe depression go into remission.
-
-
“Brain stimulation, if used carefully and safely, looks promising, especially if combined with other therapies,”
Harvard Health
says Dr. Daniel Press, a neurologist with the Berenson-Allen Center for Noninvasive Brain Stimulation at Harvard-affiliated Beth Israel Deaconess Medical Center. Dr. Press has used noninvasive brain stimulation for almost a decade.
-
This CTV report identifies memory loss research including a Harvard report also noting small-scale studies suggested that people with mild Alzheimer’s disease could see improved function through a combination of TMS and cognitive exercises
CTVNews
-
Two complementary studies recently found that noninvasive and extremely mild brain stimulation could be used to improve episodic and working memory in older adults
CBC
-
In a new study, scientists improved memory of complex, realistic events by applying transcranial magnetic stimulation (TMS) to the brain network responsible for memory
ScienceDaily
The researchers then had participants watch videos of realistic activities to measure how memory works during everyday tasks. The findings prove it is possible to measure and manipulate realistic types of memory.
-
Dr. Sarah Tremblay worked tirelessly for two years to bring TMS to The Royal in Ottawa
Ottawa Business Journal
This dream of Dr. Tremblay’s became a reality in January 2020. The Royal’s new rTMS clinical-research platform is the first of its kind in the Ottawa region and is quickly becoming a much sought-after treatment for depression. Tremblay states, “Neuromodulation offers us a whole new way of looking at mental health treatment, where we can identify malfunctioning circuits in the brain and effectively treat them in a non-drug, non-invasive way.”
-
Calgary psychiatrist Dr. Lisa Harpur talks about the Rockyview TMS Clinic
Global News
There are a total of five RTMS clinics in Alberta: two in Calgary, two in Edmonton and one in Ponoka. Harpur said there is an ongoing initiative to bring more programs to other areas of the province but that there is currently a lack of funding to do so.
The five clinics have been working together to try to secure those funds. Each has been providing the same treatment and then collecting data from questionnaires that they have patients fill out at follow-up visits.